* From Department of Medicine, University of Washington, Seattle, WA; Department of Oral and Maxillofacial Surgery, University of California San Francisco, San Francisco, CA; Divisions of Oncology and Hematology, Duke University Medical Center, Durham, NC; and University of Rochester Medical Center, Rochester, NY.
Delivery of cancer chemotherapy is often limited by myelotoxicity, primarily neutropenia. As part of an effort to create a model to predict the risk of chemotherapy-induced neutropenia, we reviewed the reports of randomized clinical trials with more than 50 patients per arm in early-stage breast cancer (ESBC) and non-Hodgkin's lymphoma (NHL) published between 1990 and 2000. We observed that no hematologic toxicity data were reported in 39% and 34% of the ESBC and NHL trials, respectively. The remaining trials reported on hematologic toxicity in 16 different ways. When reported, rates of neutropenia, leukopenia, and hematotoxicity varied widely with the same and similar chemotherapy regimens. Dose-intensity data were not reported in 39% and 54% of ESBC and NHL trials, respectively. The majority of the remaining studies reported incomplete dose-intensity data such as percentages of patients completing all cycles or receiving a given percentage of planned dose intensity. Only 28% reported the mean or median relative dose intensity received by patients. Based on this review, we conclude that current practices for reporting chemotherapy treatments are inadequate for describing the risk of chemotherapy to patients or for quantitatively assessing the risk of treatment alternatives. We recommend that standard procedures for documenting and reporting hematologic toxicity and dose intensity in cancer chemotherapy trials be required for publication of chemotherapy trials.
If the inline PDF is not rendering correctly, you can download the PDF file here.
Correspondence: David Dale, MD, University of Washington, Department of Medicine, Box 356422, HSB, Room AA522, 1959 NE Pacific, Seattle, WA 98195-6422. E-mail: dcdale@u.washington.edu
BonadonnaG, ValagussaP, MoliterniA. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N Engl J Med1995;332:901–906.
BonadonnaGValagussaPMoliterniA. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N Engl J Med1995;332:901–906.
)| false
WoodWC, BudmanDR, KorzunAH. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med1994;330:1253–1259.
WoodWCBudmanDRKorzunAH. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med1994;330:1253–1259.
)| false
BudmanDR, BerryDA, CirrincioneCT. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst1998;90: 1205–1211.
BudmanDRBerryDACirrincioneCT. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst1998;90: 1205–1211.
)| false
EpelbaumR, FaraggiD, Ben-ArieY. Survival of diffuse large cell lymphoma: A multivariate analysis including dose intensity variables. Oncology1990;66:1124–1129.
EpelbaumRFaraggiDBen-ArieY. Survival of diffuse large cell lymphoma: A multivariate analysis including dose intensity variables. Oncology1990;66:1124–1129.
)| false
LepageE, GisselbrechtC, HaiounC. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol. Ann Oncol1993;4:651–656.
LepageEGisselbrechtCHaiounC. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol. Ann Oncol1993;4:651–656.
)| false
FisherB, AndersonS, WickerhamDL. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol1997;15:1858–1869.
FisherBAndersonSWickerhamDL. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol1997;15:1858–1869.
)| false
PiccartMJ, BiganzoliL, Di LeoA. The impact of chemotherapy dose density and dose intensity on breast cancer outcome: What have we learned?Eur J Cancer2000;36(suppl 1):S4–S10.
PiccartMJBiganzoliLDi LeoA. The impact of chemotherapy dose density and dose intensity on breast cancer outcome: What have we learned?Eur J Cancer2000;36(suppl 1):S4–S10.
)| false
CrawfordJ, OzerH, StollerR. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med1991;325:164–170.
CrawfordJOzerHStollerR. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med1991;325:164–170.
)| false
Uyl-de GrootCA, VellengaE, RuttenFF. An economic model to assess the savings from a clinical application of haematopoietic growth factors. Eur J Cancer1996;32A:57–62.
Uyl-de GrootCAVellengaERuttenFF. An economic model to assess the savings from a clinical application of haematopoietic growth factors. Eur J Cancer1996;32A:57–62.
)| false
SilberJH, FridmanM, DiPaolaRS. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol1998; 16:2392–2400.
SilberJHFridmanMDiPaolaRS. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol1998; 16:2392–2400.
)| false
SilberJH, FridmanM, ShpilskyA. Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. J Clin Oncol1998;16: 2435–2444.
SilberJHFridmanMShpilskyA. Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. J Clin Oncol1998;16: 2435–2444.
)| false
LymanGH, KudererN, GreeneJ. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer1998;34:1857–1864.
LymanGHKudererNGreeneJ. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer1998;34:1857–1864.
)| false
BlayJY, ChauvinF, Le CesneA. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol1996;14:636–643.
BlayJYChauvinFLe CesneA. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol1996;14:636–643.
)| false
IntragumtornchaiT, SutheesophonJ, SutcharitchanP. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma2000;37:351–360.
IntragumtornchaiTSutheesophonJSutcharitchanP. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma2000;37:351–360.
)| false
LymanGH, CrawfordJ, DaleD. Clinical prediction models for febrile neutropenia and relative dose intensity in patients receiving adjuvant breast cancer chemotherapy (Abstr. #1571). Proc Am Soc Clin Oncol2001;20:394a.
LymanGHCrawfordJDaleD. Clinical prediction models for febrile neutropenia and relative dose intensity in patients receiving adjuvant breast cancer chemotherapy (Abstr. #1571). Proc Am Soc Clin Oncol2001;20:394a.
)| false
National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Common toxicity criteria, version 2.0.1999. Available from: URL: http://ctep.info.nih.gov
National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Common toxicity criteria, version 2.0.1999. Available from: URL: http://ctep.info.nih.gov)| false
BuddGT, GreenS, O'BryanRM. Short-course FACM versus 1-year of CMFVP in node-positive, hormone receptor-negative breast cancer: An intergroup study. J Clin Oncol1995;13:831–839.
BuddGTGreenSO'BryanRM. Short-course FACM versus 1-year of CMFVP in node-positive, hormone receptor-negative breast cancer: An intergroup study. J Clin Oncol1995;13:831–839.
)| false
CrivellariD, BonettiM, Castiglione-GertschM. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group trial VII. J Clin Oncol2000;18:1412–1422.
CrivellariDBonettiMCastiglione-GertschM. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group trial VII. J Clin Oncol2000;18:1412–1422.
)| false
Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. International Breast Cancer Study Group. J Clin Oncol1997;15:1385–1394.
Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. International Breast Cancer Study Group. J Clin Oncol1997;15:1385–1394.
)| false
TormeyDC, GrayR, GilchristK. Adjuvant chemo-hormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients: An Eastern Cooperative Oncology Group trial. Cancer1990;65:200–206.
TormeyDCGrayRGilchristK. Adjuvant chemo-hormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients: An Eastern Cooperative Oncology Group trial. Cancer1990;65:200–206.
)| false
FalksonHC, GrayR, WolbergWH. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: An Eastern Cooperative Oncology Group phase III study. J Clin Oncol1990;8: 599–607.
FalksonHCGrayRWolbergWH. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: An Eastern Cooperative Oncology Group phase III study. J Clin Oncol1990;8: 599–607.
)| false
ClahsenPC, van de VeldeCJH, WelvaartK. Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node-positive breast cancer: A joint European Organization for Research and Treatment of Cancer–Dutch Breast Cancer Working Party Study. J Clin Oncol1995;13:33–41.
ClahsenPCvan de VeldeCJHWelvaartK. Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node-positive breast cancer: A joint European Organization for Research and Treatment of Cancer–Dutch Breast Cancer Working Party Study. J Clin Oncol1995;13:33–41.
)| false
FountzilasG, PolichronisA, KatsohisK. Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients: A Hellenic Cooperative Oncology Group study. Oncology1996;53:137–146.
FountzilasGPolichronisAKatsohisK. Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients: A Hellenic Cooperative Oncology Group study. Oncology1996;53:137–146.
)| false
MariniG, MurrayS, GoldhirschA. The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer: International (Ludwig) Breast Cancer Study Group. Ann Oncol1996;7:245–250.
MariniGMurraySGoldhirschA. The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer: International (Ludwig) Breast Cancer Study Group. Ann Oncol1996;7:245–250.
)| false
FisherB, DignamJ, MamounasEP. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor–negative tumors: Eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol1996;14:1982–1992.
FisherBDignamJMamounasEP. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor–negative tumors: Eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol1996;14:1982–1992.
)| false
BartelinkH, RubensRD, van der SchuerenE. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: A European Organization for Research and Treatment of Cancer randomized phase III trial. J Clin Oncol1997;15:207–215.
BartelinkHRubensRDvan der SchuerenE. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: A European Organization for Research and Treatment of Cancer randomized phase III trial. J Clin Oncol1997;15:207–215.
)| false
FisherB, BrownAM, DimitrovNV. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol1990;8:1483–1496.
FisherBBrownAMDimitrovNV. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol1990;8:1483–1496.
)| false
CoombesRC, BlissJM, WilsJ. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol1996;14:35–45.
CoombesRCBlissJMWilsJ. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol1996;14:35–45.
)| false
FisherB, DignamJ, WolmarkN. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst1997;89: 1673–1682.
FisherBDignamJWolmarkN. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst1997;89: 1673–1682.
)| false
SennHJ, MaibachR, CastiglioneM. Adjuvant chemotherapy in operable breast cancer: Cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil: Eleven-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82. J Clin Oncol1997;15:2502–2509.
SennHJMaibachRCastiglioneM. Adjuvant chemotherapy in operable breast cancer: Cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil: Eleven-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82. J Clin Oncol1997;15:2502–2509.
)| false
PritchardKI, PatersonAHG, FineS. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: A report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. J Clin Oncol1997;15: 2302–2311.
PritchardKIPatersonAHGFineS. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: A report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. J Clin Oncol1997;15: 2302–2311.
)| false
LevineMN, GentM, HryniukWM. A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer. J Clin Oncol1990;8:1217–1225.
LevineMNGentMHryniukWM. A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer. J Clin Oncol1990;8:1217–1225.
)| false
RivkinSE, GreenS, MetchB. One versus 2 years of CMFVP adjuvant chemotherapy in axillary node–positive and estrogen receptor–negative patients: A Southwest Oncology Group study. J Clin Oncol1993;11:1710–1716.
RivkinSEGreenSMetchB. One versus 2 years of CMFVP adjuvant chemotherapy in axillary node–positive and estrogen receptor–negative patients: A Southwest Oncology Group study. J Clin Oncol1993;11:1710–1716.
)| false
PerloffM, NortonL, KorzunAH. Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non–cross-resistant regimen: A Cancer and Leukemia Group B study. J Clin Oncol1996;14:1589–1598.
PerloffMNortonLKorzunAH. Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non–cross-resistant regimen: A Cancer and Leukemia Group B study. J Clin Oncol1996;14:1589–1598.
)| false
LevineMN, BramwellVH, PritchardKI. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol1998;16:2651–2658.
LevineMNBramwellVHPritchardKI. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol1998;16:2651–2658.
)| false
De PlacidoS, PerroneF, CarlomagnoC. CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer: A single centre randomised clinical trial (Naples GUN-3 study). Br J Cancer1995;71:1283–1287.
De PlacidoSPerroneFCarlomagnoC. CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer: A single centre randomised clinical trial (Naples GUN-3 study). Br J Cancer1995;71:1283–1287.
)| false
MoliterniA, BonadonnaG, ValagussaP. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol1991;9:1124–1130.
MoliterniABonadonnaGValagussaP. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol1991;9:1124–1130.
)| false
HupperetsPSGJ, WilsJ, VolovicsL. Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patients. Ann Oncol1993;4:295–301.
HupperetsPSGJWilsJVolovicsL. Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patients. Ann Oncol1993;4:295–301.
)| false
FettingJH, GrayR, FaircloughDL. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: An Intergroup study. J Clin Oncol1998;16:2382–2391.
FettingJHGrayRFaircloughDL. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: An Intergroup study. J Clin Oncol1998;16:2382–2391.
)| false
SchollSM, FourquetA, AsselainB. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6. Eur J Cancer1994;30A:645–652.
SchollSMFourquetAAsselainB. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6. Eur J Cancer1994;30A:645–652.
)| false
JonesSE, SchottstaedtMW, DuncanLA. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. J Clin Oncol1996;14:2976–2983.
JonesSESchottstaedtMWDuncanLA. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. J Clin Oncol1996;14:2976–2983.
)| false
BlomqvistC, TiusanenK, ElomaaI. The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer: Long-term follow-up results of a randomised trial. Br J Cancer1992;66:1171–1176.
BlomqvistCTiusanenKElomaaI. The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer: Long-term follow-up results of a randomised trial. Br J Cancer1992;66:1171–1176.
)| false
ParadisoA, MangiaA, BarlettaA. Randomised clinical trial of adjuvant chemotherapy in patients with node-negative, fast-proliferating breast cancer. Drugs1993;45(suppl 2):S68–S74.
ParadisoAMangiaABarlettaA. Randomised clinical trial of adjuvant chemotherapy in patients with node-negative, fast-proliferating breast cancer. Drugs1993;45(suppl 2):S68–S74.
)| false
FumoleauP, DevauxY, Vo VanML. Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 × 6 cycles vs FEC 50 × 3 cycles vs FEC 75 × 3 cycles. The French Adjuvant Study Group. Drugs1993;45(suppl 2):S38–S45.
FumoleauPDevauxYVo VanML. Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 × 6 cycles vs FEC 50 × 3 cycles vs FEC 75 × 3 cycles. The French Adjuvant Study Group. Drugs1993;45(suppl 2):S38–S45.
)| false
GérardJP, HéryM, GedouinD. Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control—Preliminary results of a 4-arm randomised trial. The French Adjuvant Study Group. Drugs1993;45(suppl 2):S60–S67.
GérardJPHéryMGedouinD. Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control—Preliminary results of a 4-arm randomised trial. The French Adjuvant Study Group. Drugs1993;45(suppl 2):S60–S67.
)| false
FisherB, RedmondC, Legault-PoissonS. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol1990;8:1005–1018.
FisherBRedmondCLegault-PoissonS. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol1990;8:1005–1018.
)| false
FisherB, AndersonS, DeCillisA. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol1999;17:3374–3388.
FisherBAndersonSDeCillisA. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol1999;17:3374–3388.
)| false
FukutomiT, AkashiS, NanasawaT. Adjuvant six cycles of high-dose adriamycin, cyclophosphamide, methotrexate, 5-fluorouracil (ACMF) vs. 12 cycles of low-dose ACMF with tamoxifen for premenopausal, node-positive breast cancer patients: Results of a prospective randomized study. J Surg Oncol1995;60:242–246.
FukutomiTAkashiSNanasawaT. Adjuvant six cycles of high-dose adriamycin, cyclophosphamide, methotrexate, 5-fluorouracil (ACMF) vs. 12 cycles of low-dose ACMF with tamoxifen for premenopausal, node-positive breast cancer patients: Results of a prospective randomized study. J Surg Oncol1995;60:242–246.
)| false
TormeyDC, GrayR, AbeloffMD. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: An Eastern Cooperative Oncology Group trial. J Clin Oncol1992;10:1848–1856.
TormeyDCGrayRAbeloffMD. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: An Eastern Cooperative Oncology Group trial. J Clin Oncol1992;10:1848–1856.
)| false
AbeR, TsuchiyaA, KoieH. A cooperative randomized controlled study of adjuvant chemoendocrine therapy for breast cancer in Japan. Am J Clin Oncol1994;17: 103–108.
AbeRTsuchiyaAKoieH. A cooperative randomized controlled study of adjuvant chemoendocrine therapy for breast cancer in Japan. Am J Clin Oncol1994;17: 103–108.
)| false
BoccardoF, RubagottiA, BruzziP. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: Results of a multicentric Italian study. J Clin Oncol1990;8:1310–1320.
BoccardoFRubagottiABruzziP. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: Results of a multicentric Italian study. J Clin Oncol1990;8:1310–1320.
)| false
BoccardoF, RubagottiA, AmorosoD. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast cancer patients: An update at seven years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial. Eur J Cancer1992;28:673–680.
BoccardoFRubagottiAAmorosoD. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast cancer patients: An update at seven years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial. Eur J Cancer1992;28:673–680.
)| false
BoccardoF, RubagottiA, AmorosoD. Lack of effectiveness of adjuvant alternating chemotherapy in node-positive, estrogen-receptor-negative premenopausal breast cancer patients: Results of a multicentric Italian study. Cancer Invest1997;15:505–512.
BoccardoFRubagottiAAmorosoD. Lack of effectiveness of adjuvant alternating chemotherapy in node-positive, estrogen-receptor-negative premenopausal breast cancer patients: Results of a multicentric Italian study. Cancer Invest1997;15:505–512.
)| false
BonadonnaG, ZambettiM, ValagussaP. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: Ten-year results. JAMA1995;273:542–547.
BonadonnaGZambettiMValagussaP. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: Ten-year results. JAMA1995;273:542–547.
)| false
BontenbalM, van PuttenWL, BurghoutsJT. Value of estrogenic recruitment before chemotherapy: First randomized trial in primary breast cancer. J Clin Oncol2000;18: 734–742.
BontenbalMvan PuttenWLBurghoutsJT. Value of estrogenic recruitment before chemotherapy: First randomized trial in primary breast cancer. J Clin Oncol2000;18: 734–742.
)| false
BuzdarAU, HortobagyiGN, KauSW. Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer. J Clin Oncol1992;10:1540–1546.
BuzdarAUHortobagyiGNKauSW. Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer. J Clin Oncol1992;10:1540–1546.
)| false
Castiglione-GertschM, JohnsenC, GoldhirschA. The International (Ludwig) Breast Cancer Study Group trials I-IV: Fifteen-year follow-up. Ann Oncol1994;5:717–724.
Castiglione-GertschMJohnsenCGoldhirschA. The International (Ludwig) Breast Cancer Study Group trials I-IV: Fifteen-year follow-up. Ann Oncol1994;5:717–724.
)| false
ChaconR, Romero AcuñaL, BlajmanC. Less efficacy with alternating regimen as adjuvant chemotherapy in stage II node-positive breast cancer: Results at eight years (Pronacam 85). Br J Cancer1997;76:545–550.
ChaconRRomero AcuñaLBlajmanC. Less efficacy with alternating regimen as adjuvant chemotherapy in stage II node-positive breast cancer: Results at eight years (Pronacam 85). Br J Cancer1997;76:545–550.
)| false
EnomotoK, FujiwaraK, IkedaT, KatohS. Appraisal of adjuvant chemoendocrine therapy with tamoxifen plus tegafur in patients with breast cancer. Keio J Med1991;40:123–128.
EnomotoKFujiwaraKIkedaTKatohS. Appraisal of adjuvant chemoendocrine therapy with tamoxifen plus tegafur in patients with breast cancer. Keio J Med1991;40:123–128.
)| false
FisherB, RedmondC. Systemic therapy in node-negative patients: Updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst Monogr1992;11:105–116.
FisherBRedmondC. Systemic therapy in node-negative patients: Updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst Monogr1992;11:105–116.
)| false
GellerNL, HakesTB, PetroniGR. Association of disease-free survival and percent of ideal dose in adjuvant breast chemotherapy. Cancer1990;66:1678–1684.
GellerNLHakesTBPetroniGR. Association of disease-free survival and percent of ideal dose in adjuvant breast chemotherapy. Cancer1990;66:1678–1684.
)| false
HoustonSJ, RichardsMA, BentleyAE. The influence of adjuvant chemotherapy on outcome after relapse for patients with breast cancer. Eur J Cancer1993;29A:1513–1518.
HoustonSJRichardsMABentleyAE. The influence of adjuvant chemotherapy on outcome after relapse for patients with breast cancer. Eur J Cancer1993;29A:1513–1518.
)| false
Late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients. International Breast Cancer Study Group. Ann Oncol1990;1:30–35.
Late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients. International Breast Cancer Study Group. Ann Oncol1990;1:30–35.
)| false
Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. International Breast Cancer Study Group. J Clin Oncol1996;14:1885–1894.
Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. International Breast Cancer Study Group. J Clin Oncol1996;14:1885–1894.
)| false
KaufmannM, JonatW, AbelU. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer. J Clin Oncol1993;11:454–460.
KaufmannMJonatWAbelU. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer. J Clin Oncol1993;11:454–460.
)| false
KlefstromP, NuortioL. Levamisole in the treatment of advanced breast cancer: A ten-year follow-up of a randomized study. Acta Oncol1991;30:347–352.
KlefstromPNuortioL. Levamisole in the treatment of advanced breast cancer: A ten-year follow-up of a randomized study. Acta Oncol1991;30:347–352.
)| false
LevineMN, BramwellVH, Abu-ZahraH. The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation. Br J Cancer1992;65:130–132.
LevineMNBramwellVHAbu-ZahraH. The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation. Br J Cancer1992;65:130–132.
)| false
MansourEG, EudeyL, TormeyDC. Chemotherapy versus observation in high-risk node-negative breast cancer patients. J Natl Cancer Inst Monogr1992;11:97–104.
MansourEGEudeyLTormeyDC. Chemotherapy versus observation in high-risk node-negative breast cancer patients. J Natl Cancer Inst Monogr1992;11:97–104.
)| false
MansourEG, GrayR, ShatilaAH. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer patients. J Natl Cancer Inst Monogr1998;16:3486–3492.
MansourEGGrayRShatilaAH. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer patients. J Natl Cancer Inst Monogr1998;16:3486–3492.
)| false
MauriacL, DurandM, ChauvergneJ. Randomized trial of adjuvant chemotherapy for operable breast cancer comparing iv CMF to an epirubicin-containing regimen. Ann Oncol1992;3:439–443.
MauriacLDurandMChauvergneJ. Randomized trial of adjuvant chemotherapy for operable breast cancer comparing iv CMF to an epirubicin-containing regimen. Ann Oncol1992;3:439–443.
)| false
MissetJL, di PalmaM, DelgadoM. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16-year median follow-up duration. J Clin Oncol1996;14:1136–1145.
MissetJLdi PalmaMDelgadoM. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16-year median follow-up duration. J Clin Oncol1996;14:1136–1145.
)| false
MorrisonJM, KellyKA, HowellA. West Midlands Oncology Association trial of adjuvant chemotherapy in node-negative breast cancer. J Natl Cancer Inst Monogr1992;11:85–88.
MorrisonJMKellyKAHowellA. West Midlands Oncology Association trial of adjuvant chemotherapy in node-negative breast cancer. J Natl Cancer Inst Monogr1992;11:85–88.
)| false
MouraliN, TabbaneF, MuenzLR. Ten-year results utilizing chemo-therapy as primary treatment in nonmetastatic, rapidly progressing breast cancer. Cancer Invest1993;11: 363–370.
MouraliNTabbaneFMuenzLR. Ten-year results utilizing chemo-therapy as primary treatment in nonmetastatic, rapidly progressing breast cancer. Cancer Invest1993;11: 363–370.
)| false
NevilleAM, BettelheimR, GelberRD. Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group. J Clin Oncol1992;10:696–705.
NevilleAMBettelheimRGelberRD. Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group. J Clin Oncol1992;10:696–705.
)| false
NomuraY. Response to second line chemo-endocrine treatment may prolong the overall survival of advanced breast cancer patients. Anticancer Res1997;17:1425–1430.
NomuraY. Response to second line chemo-endocrine treatment may prolong the overall survival of advanced breast cancer patients. Anticancer Res1997;17:1425–1430.
)| false
NomuraY, ShirouzuM, TakayamaT. Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status. Breast Cancer Res Treat1998;49:51–60.
NomuraYShirouzuMTakayamaT. Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status. Breast Cancer Res Treat1998;49:51–60.
)| false
PisanskyTM, IngleJN, SchaidDJ. Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Cancer1993;72:1247–1260.
PisanskyTMIngleJNSchaidDJ. Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Cancer1993;72:1247–1260.
)| false
PowlesTJ, HickishTF, MakrisA. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol1995;13:547–552.
PowlesTJHickishTFMakrisA. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol1995;13:547–552.
)| false
RagazJ, JacksonSM, LeN. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med1997;337:956–962.
RagazJJacksonSMLeN. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med1997;337:956–962.
)| false
RichardsMA, O'ReillySM, HowellA. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: An update of the Guy's/Manchester trial. J Clin Oncol1990;8:2032–2039.
RichardsMAO'ReillySMHowellA. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: An update of the Guy's/Manchester trial. J Clin Oncol1990;8:2032–2039.
)| false
SauerbreiW, BastertG, BojarH. Randomized 2 × 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients: An update based on a ten-year follow-up. German Breast Cancer Study Group. J Clin Oncol2000;18:94–101.
SauerbreiWBastertGBojarH. Randomized 2 × 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients: An update based on a ten-year follow-up. German Breast Cancer Study Group. J Clin Oncol2000;18:94–101.
)| false
SchmoorC, BastertG, DunstJ. Randomized trial on the effect of radiotherapy in addition to 6 cycles CMF in node-positive breast-cancer patients. German Breast Cancer Study Group. Int J Cancer2000;86:408–415.
SchmoorCBastertGDunstJ. Randomized trial on the effect of radiotherapy in addition to 6 cycles CMF in node-positive breast-cancer patients. German Breast Cancer Study Group. Int J Cancer2000;86:408–415.
)| false
ShapiroCL, GelmanRS, HayesDF. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes. J Natl Cancer Inst1993;85:812–817.
ShapiroCLGelmanRSHayesDF. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes. J Natl Cancer Inst1993;85:812–817.
)| false
SugimachiK, MaeharaY, AkazawaK. Postoperative chemo-endocrine treatment with mitomycin C, tamoxifen, and UFT is effective for patients with premenopausal estrogen receptor-positive stage II breast cancer. Breast Cancer Res Treat1999;56:113–124.
SugimachiKMaeharaYAkazawaK. Postoperative chemo-endocrine treatment with mitomycin C, tamoxifen, and UFT is effective for patients with premenopausal estrogen receptor-positive stage II breast cancer. Breast Cancer Res Treat1999;56:113–124.
)| false
ToiM, HattoriT, AkagiM. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer: Five-year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization. Cancer1992;70:2475–2483.
ToiMHattoriTAkagiM. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer: Five-year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization. Cancer1992;70:2475–2483.
)| false
Velez-GarciaE, CarpenterJTJr, MooreM. Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: A South-Eastern Cancer Study Group (SEG) trial. Eur J Cancer1992;28A:1833–1837.
Velez-GarciaECarpenterJTJrMooreM. Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: A South-Eastern Cancer Study Group (SEG) trial. Eur J Cancer1992;28A:1833–1837.
)| false
WilsJ, CoombesRC, MartyM. Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer: A trial of the International Collaborative Cancer Group (ICCG). Drugs1993;45(suppl 2):46–50.
WilsJCoombesRCMartyM. Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer: A trial of the International Collaborative Cancer Group (ICCG). Drugs1993;45(suppl 2):46–50.
)| false
ZambettiM, ValagussaP, BonadonnaG. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-negative and estrogen receptor-negative breast cancer: Updated results. Ann Oncol1996;7:481–485.
ZambettiMValagussaPBonadonnaG. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-negative and estrogen receptor-negative breast cancer: Updated results. Ann Oncol1996;7:481–485.
)| false
ColtmanCA, DahlbergS, JonesSE. CHOP is curative in 30% of patients with large cell lymphoma: a 12-year Southwest Oncology Group follow-up, In: SkarinA, ed. Advances in Cancer Chemotherapy: Update on Treatment for Diffuse Large Cell Lymphoma.New York: Park Row, 1986:71.
ColtmanCADahlbergSJonesSE. CHOP is curative in 30% of patients with large cell lymphoma: a 12-year Southwest Oncology Group follow-up, In: SkarinA, ed. Advances in Cancer Chemotherapy: Update on Treatment for Diffuse Large Cell Lymphoma.New York: Park Row, 1986:71.
)| false
CooperIA, WolfMM, RobertsonTI. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. J Clin Oncol1994;12:769–778.
CooperIAWolfMMRobertsonTI. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. J Clin Oncol1994;12:769–778.
)| false
GordonLI, HarringtonD, AndersenJ. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med1992;327:1342–1349.
GordonLIHarringtonDAndersenJ. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med1992;327:1342–1349.
)| false
FisherRI, GaynorER, DahlbergS. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med1993;328:1002–1006.
FisherRIGaynorERDahlbergS. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med1993;328:1002–1006.
)| false
BezwodaW, RastogiRB, Erazo VallaA. Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Novantrone International Study Group. Eur J Cancer1995;31A:903–911.
BezwodaWRastogiRBErazo VallaA. Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Novantrone International Study Group. Eur J Cancer1995;31A:903–911.
)| false
TirelliU, ErranteD, Van GlabbekeM. CHOP is the standard regimen in patients ≥ 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol1998;16:27–34.
TirelliUErranteDVan GlabbekeM. CHOP is the standard regimen in patients ≥ 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol1998;16:27–34.
)| false
LinchDC, Vaughan HudsonB, HancockBW. A randomised comparison of a third-generation regimen (PACE-BOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: A British National Lymphoma Investigation report. Br J Cancer1996;74:318–322.
LinchDCVaughan HudsonBHancockBW. A randomised comparison of a third-generation regimen (PACE-BOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: A British National Lymphoma Investigation report. Br J Cancer1996;74:318–322.
)| false
MillerTP, DahlbergS, CassadyJR. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med1998;339:21–26.
MillerTPDahlbergSCassadyJR. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med1998;339:21–26.
)| false
GottliebAJ, AndersonJR, GinsbergSJ. A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851. Cancer1990;66:1888–1896.
GottliebAJAndersonJRGinsbergSJ. A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851. Cancer1990;66:1888–1896.
)| false
UnterhaltM, HerrmannR, TiemannM. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. Leukemia1996;10:836–843.
UnterhaltMHerrmannRTiemannM. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. Leukemia1996;10:836–843.
)| false
HagenbeekA, CardeP, MeerwaldtJH. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol1998;16:41–47.
HagenbeekACardePMeerwaldtJH. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol1998;16:41–47.
)| false
Solal-CélignyP, LepageE, BrousseN. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol1998;16:2332–2338.
Solal-CélignyPLepageEBrousseN. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol1998;16:2332–2338.
)| false
BastionY, BlayJY, DivineM. Elderly patients with aggressive non-Hodgkin's lymphoma: Disease presentation, response to treatment, and survival: A Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol1997;15:2945–2953.
BastionYBlayJYDivineM. Elderly patients with aggressive non-Hodgkin's lymphoma: Disease presentation, response to treatment, and survival: A Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol1997;15:2945–2953.
)| false
SertoliMR, SantiniG, ChisesiT. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol1994;12:1366–1374.
SertoliMRSantiniGChisesiT. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol1994;12:1366–1374.
)| false
KöpplerH, PflügerK-H, EschenbachI. Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: Treatment results and prognostic factor analysis in a multi-centre trial. Ann Oncol1994;5:49–55.
KöpplerHPflügerK-HEschenbachI. Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: Treatment results and prognostic factor analysis in a multi-centre trial. Ann Oncol1994;5:49–55.
)| false
BaileyNP, StuartNSA, BessellEM. Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMEt) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma. Central Lymphoma Group. Ann Oncol1998;9:633–638.
BaileyNPStuartNSABessellEM. Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMEt) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma. Central Lymphoma Group. Ann Oncol1998;9:633–638.
)| false
MeyerRM, QuirtIC, SkillingsJR. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. N Engl J Med1993;329:1770–1776.
MeyerRMQuirtICSkillingsJR. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. N Engl J Med1993;329:1770–1776.
)| false
AvilésA, DelgadoS, RuizH. Treatment of non-Hodgkin's lymphoma of Waldeyer's ring: radiotherapy versus chemotherapy versus combined therapy. Eur J Cancer B Oral Oncol1996;32B:19–23.
AvilésADelgadoSRuizH. Treatment of non-Hodgkin's lymphoma of Waldeyer's ring: radiotherapy versus chemotherapy versus combined therapy. Eur J Cancer B Oral Oncol1996;32B:19–23.
)| false
SomersR, CardeP, ThomasJ. EORTC study of non-Hodgkin's lymphoma: Phase III study comparing CHVmPVB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma. Ann Oncol1994;5(suppl 2):S85–S89[published erratum appears in Ann Oncol 1994;5:475].
SomersRCardePThomasJ. EORTC study of non-Hodgkin's lymphoma: Phase III study comparing CHVmPVB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma. Ann Oncol1994;5(suppl 2):S85–S89[published erratum appears in Ann Oncol 1994;5:475].
)| false
GisselbrechtC, HaiounC, LepageE. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: Factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte. Leuk Lymphoma1997;25: 289–300.
GisselbrechtCHaiounCLepageE. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: Factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte. Leuk Lymphoma1997;25: 289–300.
)| false
NairR, RamakrishnanG, NairNN. A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma. Cancer1998;82:2282–2288.
NairRRamakrishnanGNairNN. A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma. Cancer1998;82:2282–2288.
)| false
BertiniM, FreiloneR, BottoB. Idarubicin in patients with diffuse large cell lymphomas: A randomized trial comparing VACOP-B (A = doxorubicin) vs VICOP-B (I = idarubicin). Haematologica1997;82:309–313.
BertiniMFreiloneRBottoB. Idarubicin in patients with diffuse large cell lymphomas: A randomized trial comparing VACOP-B (A = doxorubicin) vs VICOP-B (I = idarubicin). Haematologica1997;82:309–313.
)| false
ZinzaniPL, PavoneE, StortiS. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood1997;89:3974–3979.
ZinzaniPLPavoneEStortiS. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood1997;89:3974–3979.
)| false
GerhartzHH, EngelhardM, MeusersP. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood1993;82: 2329–2339.
GerhartzHHEngelhardMMeusersP. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood1993;82: 2329–2339.
)| false
LorussoV, PalmieriG, BiancoAR. CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group. Int J Oncol2000;16:149–154.
LorussoVPalmieriGBiancoAR. CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group. Int J Oncol2000;16:149–154.
)| false
ArranzR, García-AlfonsoP, SobrinoP. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: Results from a prospective, multicenter trial with double randomization. J Clin Oncol1998;16:1538–1546.
ArranzRGarcía-AlfonsoPSobrinoP. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: Results from a prospective, multicenter trial with double randomization. J Clin Oncol1998;16:1538–1546.
)| false
JerkemanM, AndersonH, Cavallin-StahlE. CHOP versus MACOP-B in aggressive lymphoma: A Nordic Lymphoma Group randomised trial. Ann Oncol1999; 10:1079–1086.
JerkemanMAndersonHCavallin-StahlE. CHOP versus MACOP-B in aggressive lymphoma: A Nordic Lymphoma Group randomised trial. Ann Oncol1999; 10:1079–1086.
)| false
SonneveldP, de RidderM, Van der LelieH. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol1995;13:2530–2539.
SonneveldPde RidderMVan der LelieH. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol1995;13:2530–2539.
)| false
ZinzaniPL, MartelliM, StortiS. Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma1995;19:329–335.
ZinzaniPLMartelliMStortiS. Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma1995;19:329–335.
)| false
LongoDL, DeVitaVTJr, DuffeyPL. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial. J Clin Oncol1991;9:25–38[published erratum appears in J Clin Oncol 1991;9:710].
LongoDLDeVitaVTJrDuffeyPL. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial. J Clin Oncol1991;9:25–38[published erratum appears in J Clin Oncol 1991;9:710].
)| false
SilingardiV, FedericoM, CavannaL. ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: Long term results of a multicenter study of the Italian Lymphoma Study Group (GISL). Leuk Lymphoma1995;17:313–320.
SilingardiVFedericoMCavannaL. ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: Long term results of a multicenter study of the Italian Lymphoma Study Group (GISL). Leuk Lymphoma1995;17:313–320.
)| false
FedericoM, MorettiG, GobbiPG. ProMACE-cytaBOM versus MACOP-B in intermediate and high grade NHL: Preliminary results of a prospective randomized trial. Leukemia1991;5(suppl 1):95–101.
FedericoMMorettiGGobbiPG. ProMACE-cytaBOM versus MACOP-B in intermediate and high grade NHL: Preliminary results of a prospective randomized trial. Leukemia1991;5(suppl 1):95–101.
)| false
FedericoM, GobbiPG, MorettiG. Effects of thymostimulin with combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma: A report from the Italian Lymphoma Study Group (GISL). Am J Clin Oncol1995;18:8–14.
FedericoMGobbiPGMorettiG. Effects of thymostimulin with combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma: A report from the Italian Lymphoma Study Group (GISL). Am J Clin Oncol1995;18:8–14.
)| false
FedericoM, CloV, BrugiatelliM. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma: Final report of a multicenter trial conducted by GISL. Haematologica1998;83:800–811.
FedericoMCloVBrugiatelliM. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma: Final report of a multicenter trial conducted by GISL. Haematologica1998;83:800–811.
)| false
AmylonMD, ShusterJ, PullenJ. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study. Leukemia1999;13:335–342.
AmylonMDShusterJPullenJ. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study. Leukemia1999;13:335–342.
)| false
AndersonJR, JenkinRD, WilsonJF. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: A report of CCG-551 from the Childrens Cancer Group. J Clin Oncol1993;11:1024–1032.
AndersonJRJenkinRDWilsonJF. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: A report of CCG-551 from the Childrens Cancer Group. J Clin Oncol1993;11:1024–1032.
)| false
AvilésA, Diaz-MaqueoJC, SanchezE. Long-term results in patients with low-grade nodular non-Hodgkin's lymphoma: A randomized trial comparing chemotherapy plus radiotherapy with chemotherapy alone. Acta Oncol1991;30:329–333.
AvilésADiaz-MaqueoJCSanchezE. Long-term results in patients with low-grade nodular non-Hodgkin's lymphoma: A randomized trial comparing chemotherapy plus radiotherapy with chemotherapy alone. Acta Oncol1991;30:329–333.
)| false
AvilésA, NamboMJ, TalaveraA. Epirubicin (CEOP-Bleo) versus idarubicin (CIOP-Bleo) in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma: Dose escalation studies. Anticancer Drugs1997;8:937–942.
AvilésANamboMJTalaveraA. Epirubicin (CEOP-Bleo) versus idarubicin (CIOP-Bleo) in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma: Dose escalation studies. Anticancer Drugs1997;8:937–942.
)| false
BriceP, BastionY, LepageE. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol1997;15:1110–1117.
BricePBastionYLepageE. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol1997;15:1110–1117.
)| false
BrugiatelliM, FedericoM, GobbiPG. Epidoxorubicin vs idarubicin containing regimens in intermediate and high grade non-Hodgkin's lymphoma: Preliminary results of a multicentric randomized trial. Haematologica1993;78:306–312.
BrugiatelliMFedericoMGobbiPG. Epidoxorubicin vs idarubicin containing regimens in intermediate and high grade non-Hodgkin's lymphoma: Preliminary results of a multicentric randomized trial. Haematologica1993;78:306–312.
)| false
CameronDA, WhiteJM, ProctorSJ. CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Eur J Cancer1997;33:1195–1201.
CameronDAWhiteJMProctorSJ. CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Eur J Cancer1997;33:1195–1201.
)| false
CardeP, MeerwaldtJH, van GlabbekeM. Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): The 1980–1985 EORTC trial. The EORTC Lymphoma Group. Ann Oncol1991;2:431–435.
CardePMeerwaldtJHvan GlabbekeM. Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): The 1980–1985 EORTC trial. The EORTC Lymphoma Group. Ann Oncol1991;2:431–435.
)| false
CoiffierB, Neidhardt-BerardEM, TillyH. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: A GELA study. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol1999;10:1191–1197.
CoiffierBNeidhardt-BerardEMTillyH. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: A GELA study. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol1999;10:1191–1197.
)| false
EngelhardM, GerhartzH, BrittingerG. Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: Results of a randomized double-blind placebo-controlled study with intensified COP-BLAM ± rhGM-CSF. Ann Oncol1994;5(suppl 2):123–125.
EngelhardMGerhartzHBrittingerG. Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: Results of a randomized double-blind placebo-controlled study with intensified COP-BLAM ± rhGM-CSF. Ann Oncol1994;5(suppl 2):123–125.
)| false
EngelhardM, MeusersP, BrittingerG. Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: Updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy. Ann Oncol1991;2(suppl 2):177–180.
EngelhardMMeusersPBrittingerG. Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: Updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy. Ann Oncol1991;2(suppl 2):177–180.
)| false
FisherRI, DanaBW, LeBlancM. Interferon alfa consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: Results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol2000;18:2010–2016.
FisherRIDanaBWLeBlancM. Interferon alfa consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: Results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol2000;18:2010–2016.
)| false
GianniAM, BregniM, SienaS. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med1997;336:1290–1297.
GianniAMBregniMSienaS. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med1997;336:1290–1297.
)| false
KelseySM, NewlandAC, HudsonGV, JelliffeAM. A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma. Med Oncol1994;11:19–25.
KelseySMNewlandACHudsonGVJelliffeAM. A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma. Med Oncol1994;11:19–25.
)| false
KimbyE, BjorkholmM, GahrtonG. Chlorambucil/prednisone vs CHOP in symptomatic low-grade non-Hodgkin's lymphomas: A randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol1994;5(suppl 2):67–71.
KimbyEBjorkholmMGahrtonG. Chlorambucil/prednisone vs CHOP in symptomatic low-grade non-Hodgkin's lymphomas: A randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol1994;5(suppl 2):67–71.
)| false
LepageE, SebbanC, GisselbrechtC. Treatment of low-grade non-Hodgkin's lymphomas: Assessment of doxorubicin in a controlled trial. Hematol Oncol1990;8:31–39.
LepageESebbanCGisselbrechtC. Treatment of low-grade non-Hodgkin's lymphomas: Assessment of doxorubicin in a controlled trial. Hematol Oncol1990;8:31–39.
)| false
MeerwaldtJH, CardeP, SomersR. Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group. Ann Oncol1997;8(suppl 1):67–70.
MeerwaldtJHCardePSomersR. Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group. Ann Oncol1997;8(suppl 1):67–70.
)| false
PatteC, PhilipT, RodaryC. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: Results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol1991;9: 123–132.
PatteCPhilipTRodaryC. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: Results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol1991;9: 123–132.
)| false
PriceCG, RohatinerAZ, StewardW. Interferon alfa-2b in addition to chlorambucil in the treatment of follicular lymphoma: preliminary results of a randomized trial in progress. Eur J Cancer1991;27(suppl 4):S34–S36.
PriceCGRohatinerAZStewardW. Interferon alfa-2b in addition to chlorambucil in the treatment of follicular lymphoma: preliminary results of a randomized trial in progress. Eur J Cancer1991;27(suppl 4):S34–S36.
)| false
TubergenDG, KrailoMD, MeadowsAT. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: A Children's Cancer Group study. J Clin Oncol1995;13:1368–1376.
TubergenDGKrailoMDMeadowsAT. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: A Children's Cancer Group study. J Clin Oncol1995;13:1368–1376.
)| false
ZinzaniPL, MagagnoliM, MorettiL. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol2000;18:773–779.
ZinzaniPLMagagnoliMMorettiL. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol2000;18:773–779.
)| false
